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Introduction
The challenge in the development of new devices for ortho-
paedics is to ensure long-term stability, anchorage and func-
tion. The loosening of joint prosthesis, resulting in device
failure, is a major concern in the field of biomaterials for
orthopaedic applications,[1,2] with revision surgery occur-
ring at both early and late implantation periods, depending
on the cause of failure. Unpredictable adverse reactions to
some commonly used traditional implants have been report-
ed by a number of research groups.[3–7] Key factors in
device failure are believed to be the generation of wear par-
ticles and the biological response to them in periprosthetic
tissues[2,4] as well as the degradation products of biodegra-
dable materials, both resulting in osteolytic reactions.[5,6,8]
The presence of activated macrophages[9–13] or foreign-
body giant cells,[9,11,13] and the formation of a fibrous
capsule[14,15] are tissue-specific responses that have been
the focus of investigation in the evaluation of biomedical
implants. Additionally, the evaluation of angiogene-
sis[12,13,16,17] at the implant area has been realised as an
important factor with significant influence in the tissue
Summary: Implant failure is one of the major concerns in the
biomaterials field. Several factors have been related to the fail
but in general these biomaterials do not exhibit comparable
physical, chemical or biological properties to natural tissues
and ultimately, these devices can lead to chronic inflam-
mation and foreign-body reactions. Starch-based biode-
gradable materials and composites have shown promising
properties for a wide range of biomedical applications as well
as a reduced capacity to elicit a strong reaction from immune
system cells in vitro. In this work, blends of corn starch with
ethylene vinyl alcohol (SEVA-C), cellulose acetate (SCA)
and polycaprolactone (SPCL), as well as hydroxyapatite
(HA) reinforced starch-based composites, were investigated
in vivo. The aim of the work was to assess the host response
evoked for starch-based biomaterials, identifying the pres-
ence of key cell types. The tissues surrounding the implant
were harvested together with the material and processed
histologically for evaluation using immunohistochemistry.
At implant retrieval there was no cellular exudate around the
implants and no macroscopic signs of an inflammatory reac-
tion in any of the animals. The histological analysis of the
sectioned interface tissue after immunohistochemical stain-
ing using ED1, ED2, CD54, MHC class II and a/b antibodies
showed positively stained cells for all antibodies, except for
a/b for all the implantation periods, where it was different for
the various polymers and for the period of implantation.
SPCL and SCA composites were the materials that stimulat-
ed the greatest cellular tissue responses, but generally biode-
gradable starch-based materials did not induce a severe
reaction for the studied implantation times, which contrasts
with other types of degradable polymeric biomaterials.
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reaction at the polymer-tissue interface. The presence of
giant cells is frequently observed[9,11,13] and the duration
and severity of the reaction may or may not compromise the
role of the device. Phagocytic cells normally involved in
inflammation are thought to be responsible for removing the
final products of degradation. In fact, both clinical app-
lications[4–6] and animal studies[18–21] have suggested that
degradation products directly and indirectly affect tissue
remodelling by interaction with the cells responsible for the
formation of de novo tissue and through the induction of
inflammatory cytokines released by activated macro-
phages. Since macrophages tend to engulf smaller par-
ticles[22] and form multinuclear giant cells to surround
larger objects,[23] particle size was also suggested to be an
important factor in the different tissue reactions. Nonethe-
less, the differences in duration of the response may also be
related to the material properties[23] or with the angio-
genesis around an implant[12,13,16,17]. A co-dependence has
been proposed between inflammation and angiogene-
sis[24,25] due to the presence of activated macrophages,
capable of releasing numerous angiogenic growth fac-
tors.[24,26] In addition, the up-regulation of adhesion molec-
ules is known to have a significant role in the process of
transvascular migration of the inflammatory infiltrate.[27,28]
Lymphocytes have also been observed at the interface of
some implants.[18,29–31] These cells are able to secrete
various mediators which, in turn, have functions in immu-
nological and inflammatory responses. Although in the
majority of the cases they are identified in low numbers,
lymphocytes may secrete interleukin (IL)-4[32] and inter-
feron (IFN)-g[30] which can induce macrophage fusion and
activation. Studies with T-cell-deficient rats[30] have shown
that T cells play a major role in the formation of giant cells
and in the phagocytic activity of macrophages and giant
cells during the tissue response to biomaterials. Serious
complications have been demonstrated when lymphocytes
were the main type of cell found in a retrieved cell sus-
pension with a low number of mononuclear phagocytes,[29]
which suggested a lymphocyte-mediated specific immu-
nological reaction against the implant. Presenting the
possibility, the tissue reaction to biomaterials might be
modulated by controlling T-cell activation in the case of
unwanted or secondary reactions, or in the case of too-fast
degradation of biomaterials.
Starch-based materials, proposed for several biomedical
applications,[33–36] have also been shown to be degraded by
a-amylase,[37–39] phagocytosed by macrophages,[38,39] and
have demonstrated a low inflammatory tissue reaction when
implanted in both rats and mice.[39,40] In works by other
groups,[41,42] starch-based biomaterials implanted in rabbits
and goats also performed well without adverse reactions.
The host response to cross-linked high-amylose starch
(Contramid1) was found to follow the main phases of the
inflammatory and foreign-body responses to injuries
caused by implanted devices.[43–46] After 4 months only a
small residual scar was apparent macroscopically and was
related to a less severe early reaction than a skin incision and
closure with suture material sham.[39]
In this work, starch-based biomaterials were subcuta-
neously implanted in rats for different time periods in order
to evaluate their immunogenicity and the host cellular res-
ponse. The tissues surrounding the implant were harvested
together with the material and were analysed using immu-
nohistochemistry. Markers for resident and recruited
macrophages as well as for T lymphocytes were used in
order to identify the types of cells and their subpopulations
present in the implant area. Furthermore, markers for acti-
vated macrophages and for antigen presenting cells (APC)
expressing major histocompatibility complex (MHC) class
II molecules were used in order to understand the mech-
anisms and intensity of the tissue reaction.
Materials and Methods
Materials
The materials studied were (i) a 50/50 (wt.-%) blend of corn
starch and ethylene vinyl alcohol (SEVA-C, Novamont,
Italy), (ii) a 50/50 (wt.-%) blend of corn starch and cellulose
acetate (SCA, Novamont, Italy), (iii) SCA reinforced with
10, 20 and 30% (wt.) of hydroxyapatite, (iv) a 30/70 (wt.-%)
blend of corn starch and polycaprolactone (SPCL, Nova-
mont, Italy) and (v) SPCL reinforced with 10, 20 and 30%
(wt.) of hydroxyapatite (HA). The starch used to produce
the polymer was obtained from native maize. Its typical
original composition was 70% amylopectin and 30% amy-
lose (wt.-%). In the composites the average size of 90% of
the HA particles was found to be below 6.5 mm (laser
granulometry analysis). Further details on the production
and characteristics of the study materials may be found in
works by Bastioli et al.[47–49]
All the materials were processed by injection moulding
under optimised processing conditions. Samples were cut
into rectangular-shaped blocks 13 10 7 mm3, and a
hole with 5-mm diameter and 10-mm length was drilled
[Figure 1(A) and (B)]. Before implantation, the edges of the
samples were trimmed and samples were rolled for 1 week
in glass flasks to round machined edges and reduce the
magnitude of edge effects.
SEVA-C composites were not used in this study in order
to keep a reasonable number of animals and consequently
conditions, and due to the in vitro results, which suggested
being similar to the unreinforced polymer SEVA-C.
Animals and Subcutaneous Implantation
The experiments were performed in Wistar rats, anaes-
thetised using Immobilon. Four different materials were
implanted subcutaneously in the back, two either side of the
spine, for 7, 14 and 21 d, with three repeats for each material
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per time period [Figure 1(C)]. Different positions and
combinations of materials for each animal were performed
to control site-specific responses and the potential effect of
degradation products. At the end of the implantation period,
rats were sacrificed by CO2 and the tissue surrounding the
implant was carefully dissected and snap frozen using
isopentane in cardice and stored at 80 8C until sectioned.
Immunohistochemistry
Frozen serial sections (7mm) were obtained at20 8C using
a 5040 Microtome (Bright, England), mounted on
3-aminopropyl-triethoxysilane (APES)-coated slides, fixed
with acetone for 5 min, air-dried and kept short term at 4 8C
until staining.
Tissue sections were washed with phosphate buffer
saline (PBS) solution and stained using an avidin-biotin
alkaline phosphatase technique.[50] In brief: materials were
exposed to rabbit serum for 30 min, followed by primary
antibodies for 45 min at room temperature. After that time,
materials were rinsed with PBS for 5 min and incubated
with biotinylated rabbit anti-mouse IgG antibody (Dako
A/S, Denmark) for 1 h at room temperature. The avidin and
biotinylated horseradish peroxidase complex (Vector
Laboratories Ltd., UK) was added to all materials for 1 h
and the substrate reaction was developed using the Alkaline
Phosphatase Substrate Kit (Vector Laboratories Ltd., UK).
Each incubation, except the rabbit serum, was followed by
one wash with PBS buffer for 5 min. Materials were washed
and counterstained with haematoxylin and mounted in
permanent aqueous mounting medium (Serotec Ltd, UK).
Each material had one sample stained as a control replacing
the primary antibody with PBS buffer.
Antibodies
Individual leukocyte cell surface molecules were identified
using the following panel of mouse anti-rat monoclonal
antibodies: a/b (Serotec, UK) to target the a/bT-cell antigen
receptor found in 97% of peripheral T lymphocytes, ED1
(Serotec, UK) labelling monocytes and immature macro-
phages, ED2 (Serotec, UK) specific for resident/mature
macrophages, CD54 (Pharmingen, USA), which reacts
with intracellular adhesion molecule-1 (ICAM-1) express-
ed in activated macrophages and HLA-DR antibody
(Serotec, UK) which recognises MHC class II antigen
present in activated macrophages and B lymphocytes.
Results
At implant retrieval there were no macroscopic signs of a
considerable inflammatory reaction in any of the animals
and no cellular exudate was formed around the implants.
A thin fibrous capsule, invariably containing inflammatory
cellsrangingfromdiffusetoconcentrateddensity,surrounded
all implants. Table 1 presents the histological analysis of the
interfacetissueafterimmunohistochemistryusingED1,ED2,
CD54, MHC class II and a/b antibodies. A positive stain,
althoughwithdifferent intensitiesdepending onthepolymers
and on the period of implantation, was observed for all the
antibodies except for a/b. The presence of blood vessels was
also observed in the majority of the cases.
SEVA-C
The starch-ethylene vinyl alcohol blend (SEVA-C) showed,
within the studied implantation period, a mild inflammatory
reaction (Figure 2).
A moderate cellular infiltrate composed of macrophages
was observed at the tissue-material interface for all periods
Figure 1. (A) Schematic representation of the implanted mate-
rials; (B) two of the materials implanted; (C) implant positions in
the back of the rat (arrows).
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of implantation. Recruited macrophages identified using
the ED1 antibody were found in moderate amounts and were
mainly located in the tissue close to the interface with the
material [Figure 2(A)]. After 21 d of implantation however,
the staining intensity increased indicating an increase in
cellular number [Figure 2(B)]. Tissue macrophages
(ED2 positively stained) were in considerable numbers
but dispersed in the surrounding outer layers of tissue
[Figure 2(C)]. Antigen presenting cells (APC) expressing
MHC class II molecules were distributed throughout the
tissue surrounding the SEVA-C implant and also at the
tissue-material interface, suggesting that these cells could
belong to either macrophage sub-population [Figure 2(D)].
As for ED1 macrophages at 21 d of implantation the MHC
class II staining pattern seemed to be more intense.
Activated macrophages were also identified through the
expression of ICAM-1. In contrast to what was expected,
due to an increased intensity of the MHC class II staining,
the amount of cells expressing ICAM-1 did not seem to
change over time. CD54-positive cells were defining the
tissue-material interface, like the ED1 macrophages, but
they were also dispersed in the surrounding tissues like the
ED2 macrophages. Few T lymphocytes were found in the
tissue surrounding SEVA-C only at 21 d of implantation.
SCA and Composites
The results obtained for the blend of starch with cellulose
acetate (SCA), with the lowest level of inflammation for the
studied implantation periods, correlated well with in vitro
results,[51] which showed a lower number of cells from a
mixed population of monocytes/macrophages and lympho-
cytes and a reduced amount of activated macrophages on
that material. No T lymphocytes were found at the interface
or in the tissues adjacent to the implant. Low numbers of
recruited and resident macrophages were observed and
seemed to be comparable for all the times of implantation.
The staining pattern showed ED1 macrophages at the
tissue-material interface [Figure 3(A)] and ED2 macro-
phages in the outside layer of the tissue [Figure 3(B)].
The cells expressing MHC class II antibody were, in the
case of SCA [Figure 3(C)], slightly different to those ob-
served for SEVA-C [Figure 2(D)]. Comparing the staining
pattern of ED1 and ED2 macrophages with MHC class II
positive cells, it can be suggested that some of both, the
recruited and resident macrophages, expressed MHC class
II. This statement is particularly valid at 7 d of implantation
(Figure 3). For longer times the intensity of the staining at
the interface (comparable to ED1 pattern) decreased.
Table 1. Tissue reaction of subcutaneous implanted starch-based materials after immunohistochemical analysis (0: absent; 1: sparse; 2:
moderate; 3: abundant; 4: very Abundant; : negative; þ: positive).
Material Implantation time Macrophages Lymphocytes Blood vessels
d ED1 ED2 CD54 MHC class II a/b CD54
SEVA-C 7 2 2 2 2 0 
14 2 2 2 2 0 þ
21 3 2 2 3 1 
SCA 7 2 2 2 2–3 0 
14 2 2 2 2 0 þ
21 2 2 2 2 0 þ
SCAþ 10% HA 7 2 2 2 2 1 
14 2 2 2 2 1 
21 2–3 2 2–3 2 1 þ
SCAþ 20% HA 7 2 2 2 2 1 þ
14 2–3 2 2 3 1 þ
21 2–3 2 2–3 3 1 þ
SCAþ 30% HA 7 2 2 2 2–3 1 þ
14 2–3 2 2 2–3 1 þ
21 3 2 3 3–4 1 þ
SPCL 7 3 2 2 3 0 
14 3 2 3 3 1 
21 4 2 3 4 1 þ
SPCLþ 10% HA 7 2 2 2 3 1 þ
14 2 2 2 2 1 þ
21 2 3 2 3 1 þ
SPCLþ 20% HA 7 3 2 3 3 1 þ
14 3 2 3 3 1 þ
21 2 2 3 3 1 þ
SPCLþ 30% HA 7 2 2 2 2 1 þ
14 2 2 2 2 1 þ
21 2 2 2 2 2 þ
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The amount of activated macrophages, expressing
ICAM-1 at the SCA interface was moderate and compara-
ble to the results obtained for SEVA-C. From day 14, CD54-
positive cells were present at the tissue-material interface,
like at day 7, but also defining blood vessels (Figure 4),
which could indicate the influx of inflammatory cells to the
site of implantation.
In terms of tissue reaction, the implantation of the SCA
reinforced with HA induced a greater effect. While in the
presence of the SCA polymer no T lymphocytes were ob-
served, for SCA composites the T cells which were
recruited to the implantation site, although very few at
day 7, remained there up to 21 d (Figure 5).
Surprisingly, SCA with higher percentages of HA (more
distinct for 20 and 30% HA) seemed to stimulate a greater
tissue response. It could be considered that, since ED1 stain-
ing was more intense, the number of inflammatory cells
attracted to the site of implantation of SCA composites,
Figure 2. Inflammatory response to SEVA-C. Light micrographs of sections immunocy-
tochemically stained (red cells) for ED1 (A, B); ED2 (C) and MHC class II (D) and
counterstained with haematoxylin (purple cells). Explants shown here were taken after 14
(A, C, D) and 21 (B) d. I-Tissue-material interface (magnification 10).
Figure 3. Inflammatory response to SCA. Light micrographs of sections immunocytochemically stained (red cells) for ED1 (A); ED2
(B); MHC class II (C) and counterstained with haematoxylin (purple cells). Explants shown here were taken after 7 d. I-Tissue-material
interface (magnification 10).
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compared to SCA, was higher particularly at 21 d of
implantation [Figure 6(A)]. Furthermore, ICAM-1 express-
ing cells were found in the periphery of blood vessels from
day 7 for SCAþ 20% HA [Figure 6(B)] and SCAþ 30%
HA [Figure 6(C)] and only at 21 d of implantation in the
case of SCAþ 10% HA [Figure 6(D)].
The distribution pattern of recruited and resident macro-
phages did not show significant differences compared to
other materials. ED1-positive cells were mainly defining
the interface, while ED2-positive cells were dispersed
within the surrounding tissue. Cells expressing ICAM-1,
however, were more concentrated at the interface at longer
implantation periods [Figure 6(B–D)].
The pattern of cells expressing MHC class II molecules
was different in the presence of SCA composites compared
to the unreinforced material. The different percentages of
HA also demonstrated differences; a greater number of cells
appeared to express MHC class II for SCA with 20 and
30% of HA [Figure 7(A) compared to SCAþ 10% HA
[Figure 7(B)]. Additionally, after 21 d of implantation of
Figure 4. Expression of the adhesion molecule ICAM-1 in a
section immunocytochemically stained (red cells) for CD54 and
counterstained with haematoxylin (purple cells). SCA was
explanted at day 14. Positive macrophages and blood vessels are
defined. I-Tissue-material interface (magnification 10).
Figure 5. Expression of the a/b T-cell antigen receptor in a
section immunocytochemically stained (red cells) for T cells and
counterstained with haematoxylin (purple cells). SCAþ 10% HA,
day 21. I-Tissue-material interface (magnification 10).
Figure 6. Inflammatory response to SCA composites; (A, D)
SCAþ 10% HA; (B) SCAþ 20% HA; (C) SCAþ 30% HA. Light
micrographs of sections immunocytochemically stained (red cells)
for ED1 (A); CD54 (B, C, D) and counterstained with haematoxylin
(purple cells). Explants shown here were taken after (B, C) 7 and
(A, D) 21 d. I-Tissue-material interface (magnification10).
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SCAþ 30% HA, the concentration of cells expressing
MHC class II seems to increase, being dispersed all over the
tissue surrounding the implant [Figure 7(C)].
As in the case of SCA, many of the cells expressing MHC
class II were probably macrophages as the pattern of
staining was very similar to ED1.
SPCL and Composites
SPCL was the starch-based biomaterial that provoked the
strongest tissue reaction. ED1 macrophages wereabundantat
the SPCL interfaces from day 7 [Figure 8(A)], persisting for
the whole duration of the study. A high staining intensity
of the cells expressing MHC class II molecules [Figure 8(B)]
was also observed. The more intense positive cell staining
was observed for ED1 and MHC class II antibodies in the
sections obtained after 21 d of SPCL implantation.
Although not as abundant as ED1 and MHC class II
positive cells, cells expressing ICAM-1 were also
found. These were more apparent at later implantation
times, demarcating blood vessels at 21 d of implantation
[Figure 8(C)].
Figure 7. Expression of MHC class II molecule in sections
immunocytochemically stained (red cells) for APC and counter-
stained with haematoxylin (purple cells). (A, C) SCAþ 30% HA;
(B) SCAþ 10% HA. Explants shown here were taken after (A) 7
and (B, C) 21 d. I-Tissue-material interface (magnification 10).
Figure 8. Inflammatory response to SPCL. Light micrographs of
sections immunocytochemically stained (red cells) for ED1 (A);
MHC class II (B); CD54 (C) and counterstained with haematox-
ylin (purple cells). Explants shown here were taken after (A, B) 7
and (C) 21 d. I-Tissue-material interface (magnification 10).
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Cells marked with ED1 are distributed within the tissue
mainly in the close line that describes the material-tissue
interface and in the most outer layer. Many of the cells
expressing MHC class II corresponded to cells stained with
either ED1 or ED2, possibly suggesting that APC could
belong to both subpopulations. Comparing the observations
for SCA composites, the incorporation of HA in the SPCL
polymer seemed to affect the tissue reaction differently. A
rare presence of T lymphocytes at the SPCL-tissue interface
was noted from day 14. However, in the case of SPCL
composites, T lymphocytes were identified at earlier im-
plantation times (from day 7) and at moderate concen-
trations in the tissues surrounding SPCLþ 30% of HA at
21 d of implantation [Figure 9(A)].
In terms of recruited cells, the implantation of SPCL
composites did not attract as many cells as the unreinforced
material, although an intense stain for ED1 antibody seem-
ed to be observed at the SPCLþ 20% HA interface for
shorter implantation periods [Figure 9(B)]. Curiously a very
similar pattern for activated macrophages and activated
endothelium (CD54 positive) was observed between SPCL
and its composite reinforced with 20% HA. These ICAM-1
expressing cells were abundant from day 7 and were
observed both at the interface and in the surrounding tis-
sues. At the interface of the other two SPCL composites
with 10 and 30% HA, activated macrophages were found in
moderate concentrations in the same pattern of distribution.
ED2-positive cells after 21 d of the implantation of
SPCLþ 10% HA presented a different morphology. These
positive cells were present, as in the case of other materials,
in the outer layer of the tissue, but were bigger [Figure 9(C)].
For all the other composites, ED2 macrophages were
comparable in terms of morphology and pattern of distri-
bution.
A higher concentration of cells expressing MHC class II
molecules were observed, as well as for CD54, in the tissues
surrounding SPCLþ 20% HA implant. Similar results were
also found for SPCLþ 10% HA.
Discussion
The sequence of wound-healing processes can be subdivid-
ed into two phases: the inflammatory phase, which
normally takes about 2 weeks, and the repair phase. The
presence of an implant can provide a continuous inflam-
matory stimulus resulting in a prolonged inflammatory
phase, which is associated with increased cellular activity
and delayed and enhanced tissue repair. Thus, chronic
inflammation is characterised by the presence of macro-
phages, monocytes, lymphocytes and plasma cells with the
proliferation of blood vessels and connective tissue. In a
final stage, foreign-body giant cells can be found apposed to
the biomaterial surface. A granulation tissue is formed, and
fibrous encapsulation of the implant occurs.[44,52–54]
The aim of this study was to determine the presence of
important cell types in the tissue response evoked by starch-
based biomaterials subcutaneously implanted in rats. The
differential activation and expansion of distinct macro-
phage populations, the recruitment of T cells and the up-
regulation of cell-adhesion molecules were evaluated.
In this study macrophages stained with ED1, immedi-
ately migrated within the first days of implantation. For
Figure 9. Inflammatory response to SPCL composites; (A, B)
SPCLþ 30% HA; (C) SPCLþ 10% HA. (A) Expression of the a/b
T-cell antigen receptor in a section immunocytochemically stained
(red cells) for T cells; Light micrographs of sections immuno-
cytochemically stained (red cells) for ED1 (B); ED2 (C). Cells
were counterstained with haematoxylin (purple cells). Explants
shown here were taken after (B) 7 and (A, C) 21 d. I-Tissue-
material interface (magnification 10).
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some materials their number increased at longer times of
implantation; thus, the ED1-positive macrophage layer at
the implant interface was shown to vary in thickness depend-
ing on the material. Mature tissue macrophages (ED2) were
only observed in the loose connective tissue surrounding
the capsule of the implants and no significant differences
were detected with time except for SPCLþ 10% HA
implanted for 21 d.
Some research[9,55–57] has demonstrated varying behav-
iour and roles for ED1 and ED2 macrophages. ED1-positive
macrophages were shown to accumulate quickly and to be
active in phagocytosis,[9,56] while ED2 macrophages
accumulated slowly and play a role in regeneration. One
study[58] suggested that ED1 macrophages play a role in
material resorption because they mainly act at the material
interface. Khouw et al.[9] reported that giant cells were
never ED2-positive, which could suggest that resident
macrophages are not involved in the phagocytosis of
implanted biomaterials.
The results obtained for SCA composites in terms of
subpopulation distribution, in particular recruited macro-
phages, are in accordance with previous research, since it
was possible to observe that the HA reinforcement of SCA
induced stronger ED1 staining. It could be speculated that
within the studied implantation periods there was some HA
dissolution from the SCA composites. In fact, SCA is the
material with higher water uptake capability and a higher
access to the inner HA particles within the composite and a
greater susceptibility to hydrolysis at the interface polymer-
HA compared to the bulk of the material.[59] Easier access
to those interfaces could facilitate the degradation of the
material and the release of HA particles, which might
be responsible for recruitment of macrophages with the
potential to phagocytose the particles.
The mechanism of cell recruitment at the inflammation
site is still poorly defined. Some authors[9] question if ED2
macrophages migrate from the loose connective tissue into
the biomaterial where they become activated for phagocy-
tosis, losing their ED2 antigen and becoming ED1-positive
cells. Alternatively it has been suggested[10] that vascular
recruitment of blood-borne monocytes contributes to the
initial macrophage response against the material. In addi-
tion, ED2 macrophages capable of expressing MCP-1[57]
were also implied to be involved in the stimulation and
recruitment of additional macrophages.[10] The duration of
the inflammatory reaction has also been correlated with
angiogenesis around implants.[12,13,16,17] In fact, the co-
dependence of inflammation and angiogenesis has been
suggested by some authors[24,25] due to the capacity of
activated macrophages to release numerous angiogenic
factors.[24,26] The up-regulation of adhesion molecules is
also known to have significant participation in the process
of transvascular migration of the inflammatory infil-
trate.[27,28] Phagocytes adhere to endothelium through
ICAM-1; thus, the influx of macrophages was analysed
considering the expression of ICAM-1 by macrophages and
blood vessels. Angiogenesis varied with implantation times
and also with the materials implanted. A marked vascular
response with macrophages infiltrating was observed in the
tissues surrounding SCA and SPCL composites, especially
for higher percentages of HA. However, close to the im-
plants in areas of high cellularity, blood vessels were sparse.
The up-regulation of adhesion molecules is useful in the
influx of cells. Cell/cell adhesion predominantly involves
binding of ICAM-1 to CD11a or CD11b[60] and macro-
phages require this interaction to form giant cells. Fur-
thermore, the activation of T cells occurs after antigen
presentation by the macrophages with the MHC class II
molecule.[53] Activated T cells secrete cytokines and pro-
vide the necessary signals to promote and regulate humoral
and cell-mediated immune responses and inflammation. In
particular, activated T cells may secrete lymphokines like
IL-4[32] and IFN-g,[31] two cytokines involved in the
regulation of MHC class II molecules and in the formation
of FBGC. Previous studies found that at implant interface
tissue, ICAM-1 was expressed by giant cells. These multi-
nucleated cells are linked to the phagocytosis of implanted
materials and their degradation products, and are often
found on the implant side of the membrane but not deeper
within the tissue.[16,61]
There are other mechanisms by which biodegradable
biomaterials can influence the FBGC response, including
the effects of surface properties on protein adsorption and
macrophage attachment and fusion. The conformation of
adsorbed proteins in the tissue biomaterial interface may
be responsible for encouraging macrophage fusion into
FBGC.[62] Some domains of fibronectin have been directly
connected to host response and in particular to macrophage
adhesion and FBGC formation in vivo.[63] The involvement
of adsorbed fibrinogen has been reported in the attraction of
phagocytic cells to the surfaces of implanted materials.[64] It
is also known that protein adsorption is related to surface
chemistry and/or topography; thus, macrophage activation
and formation of foreign-body giant cells may be influenced
by the physico-chemical properties of the implant.[18,65]
Implants with higher water and carboxylic group content
have been shown to inhibit macrophage adhesion and fu-
sion, probably because hydrophobic interactions parti-
cipate in cell-matrix interactions.[65]
An abundant number of activated macrophages express-
ing ICAM-1 were identified after implantation of some of
the starch-based materials; however, no foreign-body giant
cells were present at any of the implantation sites. A pre-
vious in vitro work[66] revealed that lymphocytes cultured
with the materials in study did not produce IFN-g, a
cytokine involved in the formation of FBGC. In addition,
in vivo protein adsorption studies showed that although
fibronectin was clearly detected in the immediate implant
tissue interface, fibrinogen was not identified in the proxi-
mal implant area.[67] Besides these possible explanations,
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the absence of FBGC may be the consequence of the
variable rate of degradation of the starch-based material[37]
at the time point of the assay, not stimulating high pha-
gocytic activity and also of the materials physical-chemical
properties, not appropriate for macrophage adhesion and
fusion.
Conclusion
The in vivo observations validated in vitro results, confirm-
ing that the established in vitro models are reliable and
could be used to estimate a potential inflammatory reaction
provoked by newly developed biomaterials before implan-
tation.
The subcutaneous implantation of starch-based bioma-
terials in rats demonstrated that the materials possess a
weak potential to stimulate an inflammatory reaction. No
macroscopic signs of considerable inflammation were
observed and no cellular exudate was formed. For some
materials the number of recruited macrophages increased at
longer times of implantation. Contrarily, mature tissue
macrophages were only observed in the loose connective
tissue surrounding the capsule of the implants and no sig-
nificant differences were detected with increasing implan-
tation time except for SPCLþ 10% HA implanted for 21 d.
This study also demonstrated a significant increase in
antigen-presenting phenotype at the interface with some
materials, which could be associated with persistent local
chronic inflammation. However, the low number or absence
of lymphocytes at some material-tissue interfaces may be
indicative of a mild foreign-body reaction against these
materials.
SPCL and SCA composites were the materials that sti-
mulated the greatest tissue responses, but in general, bio-
degradable starch-based materials did not induce a severe
reaction at the studied implantation times, which contrasts
favourably other types of degradable polymeric biomate-
rials.
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